Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
NCT ID: NCT03155243
Last Updated: 2021-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
155 participants
OBSERVATIONAL
2017-06-20
2020-02-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
NCT00525902
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
NCT01138657
Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
NCT02706704
Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis
NCT05105347
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
NCT05523765
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants receiving adalimumab (Humira®)
Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 years at the time of the enrollment.
* Diagnosis of active NIIPP uveitis as defined by the presence of at least 1 of the following parameters:
1. Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
2. \>= 2+ anterior chamber cells \[Standardization of Uveitis Nomenclature (SUN) criteria\]
3. \>= 2+ vitreous haze \[National Eye Institute (NEI)/SUN criteria\]
* Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines.
* Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study.
Exclusion Criteria
* Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments.
* Participants currently participating in other clinical research.
* Participants who are unwilling or unable to complete the quality of life and other patient reported questionnaires.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Universität Graz /ID# 206301
Graz, Styria, Austria
Medical University of Vienna /ID# 206190
Vienna, Vienna, Austria
Clinica Oftalmologica del Caribe /ID# 206448
Barranquilla, Atlántico, Colombia
Foscal /Id# 207362
Bucaramanga, , Colombia
Fundacion hospitalaria San Vicente de Paul /ID# 208295
Medellín, , Colombia
Vseobecna Fakultni Nemocnice /ID# 209530
Prague, , Czechia
Charite Campus Virchow-Klinikum /ID# 204879
Berlin, , Germany
Universitätsklinikum Hamburg-Eppendorf /ID# 205234
Hamburg, , Germany
St. Franziskus Hosp Muenster /ID# 206695
Münster, , Germany
Omma /Id# 163750
Athens, , Greece
Athens Eye Hospital /ID# 163751
Athens, , Greece
University General Hospital of Ioannina /ID# 163752
Ioannina, , Greece
Interbalkan Medical Center /ID# 163753
Thessaloniki, , Greece
Semmelweis Egyetem /ID# 163647
Budapest, , Hungary
Szegedi Tudomanyegyetem /ID# 163646
Szeged, , Hungary
Royal Victoria Eye and Ear Hos /ID# 163653
Dublin, , Ireland
Hadassah Medical Center /ID# 169305
Jerusalem, Jerusalem, Israel
Rabin Medical Center /ID# 163108
Petakh Tikva, Tel Aviv, Israel
Tel Aviv Sourasky Medical Ctr /ID# 163024
Tel Aviv, Tel Aviv, Israel
Barzilai Medical Center /ID# 163025
Ashkelon, , Israel
Bnai Zion Medical Center /ID# 163026
Haifa, , Israel
Sheba Medical Center /ID# 163109
Ramat Gan, , Israel
Albahar Ophtalmology Center /ID# 210124
Kuwait City, , Kuwait
American University of Beirut /ID# 210122
Beirut, , Lebanon
Stadtspital Triemli /ID# 206204
Zurich, Canton of Zurich, Switzerland
Inselspital, Universitaetsklinik /ID# 201027
Bern, , Switzerland
Hop Ophtalmique Jules Gonin /ID# 201028
Lausanne, , Switzerland
Cleveland Clinic Abu Dhabi /ID# 210123
Abu Dhabi, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P16-537
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.